FDA‑authorized AI Clairity recently launched an FDA-authorized AI platform for breast cancer risk prediction, signaling maturity in regulatory approval and a compelling case study for hospital networks seeking compliant AI screening solutions.

Strategic Partnerships The partnership with MagView highlights penetration into imaging workflow ecosystems, presenting a sales path to integrate Clairity's AI risk models with existing radiology information systems and image management platforms.

Leadership Recognition CEO and founder Connie Lehman has gained TIME100 Health List recognition, reinforcing credibility and creating a strong narrative for engaging C-suite stakeholders at hospitals and health systems.

Series B Momentum Significant Series B financing coupled with FDA authorization and RSNA participation demonstrates growing investor confidence and market validation, signaling readiness for scaled deployment and multi-center adoption.

Global Outreach RSNA and international collaboration across five studies indicate a path to international expansion and multi-center validation, offering opportunities to land large hospital networks and regional health systems seeking standardized AI risk assessment.